Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.54 |
| ▸ | MPL | P40238 | 8/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338082 | 0.82 | SCD (0.62) | MEN1KMT2AMAPTADORA3ALDH1A1 | |
| SCHEMBL6252950 | 0.82 | KDM4E (0.63) | MEN1KMT2AMAPTCSNK2A2CSNK2B | |
| SCHEMBL6225763 | 0.80 | MAPT (0.60) | MEN1KMT2AMAPTCSNK2A2CSNK2B | |
| SCHEMBL6252757 | 0.78 | ALOX5 (0.67) | MEN1KMT2AMAPTCSNK2A2CSNK2B | |
| SCHEMBL7238814 | 0.74 | RAB9A (0.64) | MEN1KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL24107602 | 0.74 | ADORA3 (0.71) | MEN1KMT2AMAPTMPLADORA3 | |
| SCHEMBL24107726 | 0.74 | ADORA3 (0.71) | MEN1KMT2AMAPTMPLADORA3 | |
| SCHEMBL24090295 | 0.73 | LMNA (0.71) | MEN1KMT2AMAPTNPC1ALDH1A1 | |
| SCHEMBL24107621 | 0.73 | LMNA (0.65) | MEN1KMT2AMAPTMPLADORA3 | |
| SCHEMBL2753997 | 0.73 | KMT2A (0.73) | MEN1KMT2AMAPTCSNK2A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | MEN1 4471/4885KMT2A 3796/4885MAPT 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.